/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Research To Practice | Oncology Videos
  2. Endometrial Cancer — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer
Endometrial Cancer — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Endometrial Cancer — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Research To Practice | Oncology Videos · Sep 11, 2026

Experts discuss advanced endometrial cancer treatment, debating immunotherapy, PARP inhibitors, radiation, and molecular-driven sequencing.

Oncologists Skip Routine Scans for Asymptomatic Patients on Maintenance Immunotherapy

For endometrial cancer patients stable on maintenance immunotherapy without symptoms, experts advocate against routine surveillance scans. Scans are reserved for the point when discontinuing therapy is considered, to establish a new baseline and monitor for rapid recurrence post-treatment, thus avoiding unnecessary radiation and patient anxiety.

Endometrial Cancer — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer thumbnail

Endometrial Cancer — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Research To Practice | Oncology Videos·2 months ago

Future Endometrial Cancer Progress Hinges on ADCs and Defining Treatment Duration

While antibody-drug conjugates (ADCs) are an exciting frontier in endometrial cancer, a critical challenge is emerging: determining optimal duration for maintenance therapies. Experts are concerned about committing patients to long-term, potentially toxic treatments without clear stopping rules, a key question for future trials.

Endometrial Cancer — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer thumbnail

Endometrial Cancer — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Research To Practice | Oncology Videos·2 months ago

Radiation Therapy in Endometrial Cancer Primarily Benefits the NSMP Molecular Subgroup

Contrary to broad application, data suggests radiation's main benefit in endometrial cancer is for patients in the non-specific molecular profile (NSMP) group. This molecularly-defined approach refines adjuvant treatment decisions, moving away from a one-size-fits-all strategy based on stage alone.

Endometrial Cancer — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer thumbnail

Endometrial Cancer — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Research To Practice | Oncology Videos·2 months ago

Hormonal Therapy Can Induce Responses in Low-Grade Cancers After Chemotherapy Fails

In low-grade, recurrent endometrial cancer, patients who show stable or progressive disease on chemotherapy can surprisingly respond to hormonal therapies like progesterone. Although the response may be slow, it highlights an important, potentially overlooked option for this specific patient population.

Endometrial Cancer — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer thumbnail

Endometrial Cancer — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Research To Practice | Oncology Videos·2 months ago

Experts Urge Caution Adding PARP Inhibitors to Immunotherapy for Endometrial Cancer

Despite a plausible biologic rationale, adding PARP inhibitors to chemotherapy and immunotherapy for endometrial cancer has shown minimal benefit and potential for harm. Clinicians await final overall survival (OS) data before adopting this strategy, citing a lack of convincing evidence from recent trials.

Endometrial Cancer — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer thumbnail

Endometrial Cancer — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Research To Practice | Oncology Videos·2 months ago